Evidence map›Paper›PMID 41291732›Full record

ArticleJournal of translational medicine2025

Lipid deprivation amplifies type I IFN responses in monocytes through prenylation: insights from familial combined hypolipidemia type 2.

Alessandra Pinzon Grimaldos, Ilenia Pacella, Tiziano Giacomelli, Simone Bini, Alessia Di Costanzo, Ilenia Minicocci, Laura D'Erasmo, Giuseppe Pietropaolo, Valerio Licursi, Marcello Arca and 1 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alessandra Pinzon GrimaldosDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Ilenia PacellaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Tiziano GiacomelliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Simone BiniDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Alessia Di CostanzoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Ilenia MinicocciDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Laura D'ErasmoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Giuseppe PietropaoloIRCCS Neuromed, Pozzilli, Italy.
Valerio LicursiInstitute of Molecular Biology and Pathology (IBPM), National Research Council (CNR) of Italy c/o Department of Biology and Biotechnology "C. Darwin", Sapienza University of Rome, Rome, Italy.
Marcello ArcaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Silvia PiconeseDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. silvia.piconese@uniroma1.it.ORCID http://orcid.org/0000-0002-9685-5227

Funding

Fondazione AIRC per la ricerca sul cancro ETS AIRC Fellowship for Italy 2024Fondazione AIRC per la ricerca sul cancro ETS IG-2017 19784, IG-2022 27070Foundation for the National Institutes of Health R01HL159171Istituto Pasteur-Fondazione Cenci Bolognetti Call 2019 under 45Ministero della Salute GR-2019-12368551Next Generation EU - PNRR M6C2 PNRR-MAD-2022-12375947Sapienza Università di Roma AR123188B40F7A53Sapienza Università di Roma Progetto Ateneo 2006Sapienza Università di Roma RP120172A7CBD322, RP1221815D5FEE2F
6 · The paper itself

Abstract

Familial Combined Hypolipidemia (FHBL2) is a genetic disorder caused by loss-of-function mutations in the Angiopoietin-like 3 (ANGPTL3) gene. FHBL2 subjects exhibit hypolipidemia and protection from atherosclerotic cardiovascular diseases. Here, we explored the hypothesis that immunometabolic events contribute to this atheroprotective phenotype. To this aim, circulating monocytes from FHBL2 subjects and controls were profiled through gene expression and phenotypic analysis in vivo and ex vivo. In parallel, immune responses were analyzed in monocytes that were lipid-deprived in vitro. In FHBL2 subjects, leukocytes exhibited lower content of intracellular lipids, together with a spontaneous type I IFN signature in vivo and higher sensitivity to IFN stimulation ex vivo. Lipid restriction in vitro was sufficient to recapitulate the higher IFN sensitivity in monocytes, while activating the mevalonate and isoprenoid synthetic pathway. These two events were linked, since a prenylation inhibitor reverted the high IFN response under lipid deprivation. Finally, we found that lipid restriction repressed, in a prenylation- and IFN-dependent fashion, the production of the inflammatory and proatherogenic cytokine IL-1β, and suppressed mitochondrial metabolism, which is a known trigger for inflammasome activation. In summary, we uncovered a novel immunometabolic mechanism linking lipid deprivation in monocytes, isoprenoid synthesis, enhanced IFN response, and IL-1β control. This circuit may provide an immunometabolic basis for the protection from atherosclerotic diseases in hypolipidemic subjects.

Indexed as

Interferon Type ILipid MetabolismLipidsMonocytesPrenylationAdultFemaleHumansInterleukin-1betaMaleMiddle AgedMitochondriaInterferon Type IInterleukin-1betaLipidsCholesterolImmunometabolismInterferon signatureIsoprenoids

Identifiers

PMID41291732
PMCPMC12764162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.